Related Experiment Video
Updated: May 18, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
Strategies to reduce diabetes disparities: an update
Joseph R Betancourt1, Jason V Duong, Matthew R Bondaryk
1The Disparities Solutions Center, Mongan Institute for Health Policy, Massachusetts General Hospital, 50 Staniford Street, Suite 901, Boston, MA 02114, USA. jbetancourt@partners.org
Abstract:
Racial and ethnic minorities in the US have a higher prevalence, as well as suffer from more complications, lower quality care, and poorer outcomes for diabetes than their counterparts. Given the US health care system is in the midst of drastic transformation, with the passage of health care reform, and efforts in payment reform, and value-based purchasing, there is now support to provide more intensive, team-based care for those conditions that are complex, costly, and highly prevalent. Addressing and improving diabetes disparities, given they are prevalent and costly, will be an important area of focus in the years to come. The latest research demonstrates that community-based efforts, multifactorial approaches, and the deployment of health information technology can be successful in addressing diabetes disparities, and require support, attention, resources, and continued evaluation. Ultimately, these efforts should improve the quality of care for all persons with diabetes, especially those who are most vulnerable.
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational
Atherosclerosis III: Management
Diabetes: Symptoms, Diagnosis, and Complications
Oral Hypoglycemic Agents: Biguanides and Glitazones